EUVIMEDEUVIMED entdecken
Crossref

L26/O-269 Optimising Oocyte Competence in POSEIDON 3&4 Patients: A Prospective Paired-Cycle Evaluation of Recombinant FSH with hMG-Derived LH Activity versus Recombinant FSH plus Recombinant LH

S. Baxi, V. Yakasiri, D.R. Gedela, K.C. Mantravadi

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Baxi und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question In POSEIDON 3-4 poor responders, does ovarian-stimulation with recombinant-FSH plus recombinant-LH improve ovarian-efficiency and embryo-developmental outcomes compared with recombinant-FSH with hMG-derived LH activity? Summary answer In POSEIDON 3-4 patients, recombinant-FSH plus recombinant-LH improved ovarian sensitivity, oocyte-competence, and embryo-utilisation compared with rFSH+hMG stimulation, while benefits were limited in normoresponders. What is known already POSEIDON groups 3 and 4 represent IVF patients with reduced ovarian reserve and impaired ovarian sensitivity, leading to increased biological attrition before embryo transfer. Conventional stimulation protocols are predominantly FSH-based and often supplemented with hMG, providing hCG-derived LH activity. However, hCG and LH differ in receptor binding and downstream steroidogenic signalling. Recombinant LH offers predictable, physiological LH receptor activation and may enhance follicular and oocyte competence in biologically compromised ovaries, although prospective within-patient evidence in POSEIDON populations remains limited. Study design, size, duration This was a prospective-observational-paired-cycle study conducted between January 2022-December 2024. A total of 170-women undergoing IVF were included. Based on ovarian reserve and response characteristics, patients were classified as POSEIDON 3/4 poor responders(n = 110) or Normoresponders(n = 60). All patients underwent two-consecutive-IVF cycles, serving as their own controls: an initial-cycle using recombinant-FSH with hMG-derived LH activity(rFSH + hMG), followed by a subsequent cycle using recombinant FSH plus recombinant-LH in a fixed(2:1)ratio. The primary analysis focused on POSEIDON poor-responders. Participants/materials, setting, methods .Women 21–45years were recruited after counselling and written informed-consent. POSEIDON-classification was applied prospectively using age, ovarian-reserve-markers, and ovarian-response. Controlled-ovarian-stimulation, monitoring, trigger, oocyte-retrieval, ICSI, and extended-blastocyst-culture were performed according to institutional SOPs. Outcomes were assessed up to the blastocyst stage. Key-performance-indicators included ovarian sensitivity index (OSI), follicle-to-oocyte index, fertilisation, blastocyst formation, blastocyst failure, and embryo utilisation. Paired statistical analyses were performed comparing rFSH + hMG and rFSH + rLH cycles within individuals. Main results and the role of chance In paired-cycle analysis of POSEIDON-poor responders(n = 110), stimulation with rFSH + rLH was consistently associated with improved-ovarian-efficiency and downstream-embryo developmental competence compared with the prior rFSH + hMG cycle. The rFSH + rLH cycle demonstrated enhanced-ovarian-sensitivity, reflected by a significantly lower OSI (1309 vs 1456, p < 0.05), alongside improved follicle-to-oocyte conversion (81.3%vs70.5%, p < 0.01). Fertilisation rates also increased from 81% to 90% (p < 0.05), indicating improved oocyte-competence.These upstream improvements translated into reduced biological-attrition during embryo development. Blastocyst-failure decreased from 29.3% to 15.3%, representing a 57% reduction in the odds of blastocyst-failure(OR 0.43, 95% CI 0.25–0.74), while blastocyst formation increased from 30.3% to 42%(p < 0.01), resulting in higher embryo-utilisation. Receiver-operating-characteristic-analysis demonstrated improved discrimination of OSI for blastocyst formation following rFSH + rLH stimulation (AUC 0.72) compared with the rFSH + hMG cycle (AUC 0.61).In contrast, normoresponders (n = 60) showed only modest changes in ovarian sensitivity, with no significant differences in fertilisation, blastocyst formation, or embryo utilisation, indicating that the benefit of recombinant LH was largely confined to poor responders.Overall, recombinant LH supplementation was associated with improved ovarian sensitivity, enhanced oocyte competence, and reduced biological attrition in POSEIDON 3 and 4 poor responders, with minimal incremental benefit observed in normoresponders. Limitations, reasons for caution This was a non-randomised observational study with sequential treatment exposure. As patients underwent recombinant LH stimulation following a prior unsuccessful cycle, some improvement may reflect cumulative clinical optimisation. The paired design reduces inter-individual biological variability. Single ethnicity and unanalysed male factors remain limitations. Wider implications of the findings .These within-patient findings suggest that replacing hMG-derived LH activity with physiologic recombinant LH may optimise ovarian efficiency and reduce biological attrition in POSEIDON 3&4 patients. The data support individualised stimulation strategies in poor-prognosis women and provide a rationale for future randomised crossover trials evaluating cumulative live birth and cost-effectiveness. Trial registration number No

Zitieren

APA

Baxi, S., Yakasiri, V., Gedela, D., & Mantravadi, K. (2026). L26/O-269 Optimising Oocyte Competence in POSEIDON 3&4 Patients: A Prospective Paired-Cycle Evaluation of Recombinant FSH with hMG-Derived LH Activity versus Recombinant FSH plus Recombinant LH. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.267

Vancouver

Baxi S, Yakasiri V, Gedela D, Mantravadi K. L26/O-269 Optimising Oocyte Competence in POSEIDON 3&4 Patients: A Prospective Paired-Cycle Evaluation of Recombinant FSH with hMG-Derived LH Activity versus Recombinant FSH plus Recombinant LH. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.267

BibTeX
@article{Baxi2026,
  author = {Baxi, S. and Yakasiri, V. and Gedela, D.R. and Mantravadi, K.C.},
  title = {L26/O-269 Optimising Oocyte Competence in POSEIDON 3&4 Patients: A Prospective Paired-Cycle Evaluation of Recombinant FSH with hMG-Derived LH Activity versus Recombinant FSH plus Recombinant LH},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.267}
}
Kostenlos starten →